Ramiprilum [Latin] Brand names, Ramiprilum [Latin] Analogs
Ramiprilum [Latin] Brand Names Mixture
Ramiprilum [Latin] Chemical_Formula
Ramiprilum [Latin] RX_link
Ramiprilum [Latin] fda sheet
Ramiprilum [Latin] msds (material safety sheet)
Ramiprilum [Latin] Synthesis Reference
E. H. Gold et al., U.S. Pat. 4,587,258 (1967).
Ramiprilum [Latin] Molecular Weight
Ramiprilum [Latin] Melting Point
Ramiprilum [Latin] H2O Solubility
Ramiprilum [Latin] State
Ramiprilum [Latin] LogP
Ramiprilum [Latin] Dosage Forms
Ramiprilum [Latin] Indication
For diuretics and digitalis in congestive heart failure as adjunctive therapy and for use in prophylaxis in post MI.
Ramiprilum [Latin] Pharmacology
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor similar to benazepril, fosinopril, and quinapril. An inactive prodrug, ramipril is converted to ramiprilat in the liver and is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients.
Ramiprilum [Latin] Absorption
The extent of absorption is at least 50-60% and is not significantly influenced by the presence of food in the GI tract, although the rate of absorption is reduced.
Ramiprilum [Latin] side effects and Toxicity
The most likely clinical manifestations would be symptoms attributable to hypotension. LD50 = 10933 mg/kg (orally in mice).
Ramiprilum [Latin] Patient Information
Pregnancy: Female patients of childbearing age should be told about the consequences of second- and
third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to
have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients
should be asked to report pregnancies to their physicians as soon as possible.
Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors,
especially following the first dose. Patients should be so advised and told to report immediately any signs or
symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no
more drug until they have consulted with the prescribing physician.
Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially
during the first days of therapy, and it should be reported. Patients should be told that if syncope occurs, ramipril
should be discontinued until the physician has been consulted.
All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can
lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.
Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without
consulting their physician.
Neutropenia: Patients should be told to promptly report any indication of infection (e.g.,
sore throat, fever), which could be a sign of neutropenia.
Ramiprilum [Latin] Organisms Affected
Humans and other mammals